Dianthus Therapeutics (DNTH) Financials: History & Chart

Dianthus Therapeutics, Inc.(DNTH)

Biotechnology · New York, NY

$85.40-2.64 (-3.00%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

New York, NY

92 employees

dianthustx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Marino Garcia

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.90M	761K	463K	284K	396K	193K	1.16M	1.33M	2.17M
Cost of Goods Sold	76K	0.00	76K	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	1.83M	761K	387K	284K	396K	193K	1.16M	1.33M	2.17M
Gross Profit Margin	96.0%	100.0%	83.6%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	219.67M	62.24M	46.92M	69.83M	40.68M	35.12M	34.34M	33.24M	32.07M
Research & Development	175.60M	48.69M	34.53M	59.90M	32.49M	26.25M	27.00M	26.41M	25.54M
Selling, General & Administrative	44.15M	13.56M	12.47M	9.93M	8.20M	8.87M	7.34M	6.83M	6.53M
Operating Income (EBIT)	-217.84M	-61.48M	-46.53M	-69.54M	-40.29M	-34.93M	-33.18M	-31.92M	-29.90M
Operating Margin	-11441.4%	-8079.1%	-10050.3%	-24486.3%	-10173.7%	-18096.9%	-2852.7%	-2406.9%	-1376.6%
Income Before Tax (EBT)	-29.91M	-50.22M	-40.83M	97.91M	-36.77M	-31.63M	-29.51M	-28.44M	-25.17M
Interest Income	26.73M	11.54M	6.26M	5.27M	3.66M	3.40M	3.79M	3.99M	4.45M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	187.94M	11.27M	5.70M	167.45M	3.52M	3.30M	3.67M	3.48M	4.73M
Net Income	-29.91M	-50.22M	-40.83M	97.91M	-36.77M	-31.63M	-29.51M	-28.44M	-25.17M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-1570.9%	-6598.6%	-8819.4%	34473.6%	-9284.1%	-16388.1%	-2537.5%	-2144.8%	-1159.0%
EBITDA	-217.44M	-61.45M	-46.46M	-69.28M	-40.26M	-34.83M	-33.04M	-31.84M	-29.78M
EBITDA Margin	-11420.4%	-8074.2%	-10033.9%	-24395.1%	-10166.9%	-18045.6%	-2841.3%	-2401.1%	-1371.3%
Depreciation & Amortization	399K	37K	76K	259K	27K	99K	133K	78K	116K
EPS Basic	-0.13	-0.90	-0.85	2.59	-0.97	-0.88	-0.82	-0.81	-0.74
EPS Diluted	-0.13	-0.90	-0.85	2.59	-0.97	-0.88	-0.82	-0.81	-0.74
Weighted Average Basic Shares	56.03M	56.03M	48.03M	37.79M	37.79M	35.82M	35.79M	35.03M	34.24M
Weighted Average Diluted Shares	56.03M	56.03M	48.03M	37.79M	37.79M	35.82M	35.79M	35.03M	34.24M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	2.04M	6.24M	2.83M	6.42M	1.48M	0.00	0.00	0.00
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	1.98M	1.84M	875K
Gross Profit	2.04M	6.24M	2.83M	6.42M	1.48M	-1.98M	-1.84M	-875K
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	N/A	N/A	N/A
Total Operating Expenses	179.97M	108.10M	51.00M	36.12M	14.56M	76.72M	81.13M	59.09M
Research & Development	145.64M	83.11M	32.84M	29.38M	12.61M	48.64M	57.37M	41.34M
Selling, General & Administrative	34.33M	24.99M	18.16M	6.74M	1.96M	28.09M	23.76M	17.75M
Operating Income (EBIT)	-177.93M	-101.86M	-48.17M	-29.70M	-13.09M	-78.70M	-82.97M	-59.96M
Operating Margin	-8739.3%	-1633.7%	-1704.7%	-462.9%	-886.6%	N/A	N/A	N/A
Income Before Tax (EBT)	-162.34M	-84.97M	-43.55M	-28.48M	-13.11M	-74.94M	-76.77M	-57.52M
Interest Income	16.12M	17.36M	4.76M	1.15M	100K	3.77M	N/A	2.45M
Interest Expense	N/A	N/A	N/A	N/A	N/A	3.77M	N/A	N/A
Other Income/Expense	15.60M	16.89M	4.62M	1.23M	-23K	3.77M	6.20M	2.45M
Net Income	-162.34M	-84.97M	-43.55M	-28.48M	-13.11M	-74.94M	-76.77M	-57.52M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-7973.3%	-1362.8%	-1541.2%	-443.8%	-888.1%	N/A	N/A	N/A
EBITDA	-177.50M	-101.45M	-47.82M	-29.56M	-11.07M	-76.72M	-81.13M	-59.09M
EBITDA Margin	-8718.3%	-1627.1%	-1692.1%	-460.6%	-749.7%	N/A	N/A	N/A
Depreciation & Amortization	428K	412K	355K	147K	2.02M	1.98M	1.84M	875K
EPS Basic	-4.20	-2.55	-8.45	-7.60	-3.82	-27.30	-33.18	-27.62
EPS Diluted	-4.20	-2.55	-8.45	-7.60	-3.82	-27.30	-33.18	-27.62
Weighted Average Basic Shares	37.79M	33.31M	5.15M	3.75M	3.43M	2.75M	2.31M	2.08M
Weighted Average Diluted Shares	37.79M	33.31M	5.15M	3.75M	3.43M	2.75M	2.31M	2.08M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.